NTRA
HealthcareNatera Inc
Live · NASDAQ · May 9, Close
What's Moving NTRA Today?
No stock-specific AI insight has been generated for NTRA yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Trading
NTRA News
22 articles- Natera Q1 Earnings Call HighlightsMarketbeat·May 8, 2026
- Natera (NTRA) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·May 7, 2026
- Natera (NTRA) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·May 7, 2026
- Natera NTRA Q1 2026 Earnings Call TranscriptMotley Fool·May 7, 2026
- Natera’s (NASDAQ:NTRA) Q1 CY2026 Sales Top EstimatesYahoo Finance·May 7, 2026
- Natera Reports First Quarter 2026 Financial ResultsYahoo Finance·May 7, 2026
- Why The Dip In TEM Stock Is A Buying WindowTrefis·May 6, 2026
- Natera Inc. (NTRA): Billionaire Tom Steyer’s Stock Pick with Huge Upside PotentialYahoo Finance·May 3, 2026
- William Blair Initiates Natera (NTRA) With OutperformYahoo Finance·May 2, 2026
- Extreme Networks And 2 Additional Stocks Estimated To Be Trading Below Their Fair ValueYahoo Finance·May 1, 2026
- Alignment Healthcare (ALHC) Q1 Earnings and Revenues Top EstimatesYahoo Finance·Apr 30, 2026
- Exploring High Growth US Tech Stocks This April 2026Yahoo Finance·Apr 30, 2026
- Natera to Report its First Quarter Results on May 7, 2026Yahoo Finance·Apr 30, 2026
- Should You Be Bullish on Natera (NTRA)?Yahoo Finance·Apr 29, 2026
- Is It Too Late To Consider Natera (NTRA) After Its Strong Multi Year Share Price Run?Yahoo Finance·Apr 25, 2026
- Prospera™ Evidence in Heart and Lung Transplantation Featured Across 17 Presentations at ISHLTYahoo Finance·Apr 22, 2026
- Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)Yahoo Finance·Apr 21, 2026
- 3 Reasons We’re Fans of Natera (NTRA)Yahoo Finance·Apr 20, 2026
- Natera, UFP Technologies, Mettler-Toledo, and Viatris Shares Are Soaring, What You Need To KnowYahoo Finance·Apr 18, 2026
- 1 Cash-Producing Stock to Own for Decades and 2 That UnderwhelmYahoo Finance·Apr 15, 2026
- Natera Positioned To Capture Growing $20 Billion MRD Opportunity-AnalystBenzinga·Apr 14, 2026
- Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip SurgeryBenzinga·Mar 31, 2026
All 22 articles loaded
Price Data
Fundamentals
Trading
About Natera Inc
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.